COVID-19 Evidence Review Group for Medicines
The COVID-19 Evidence Review Group for Medicines was established in March 2021 to support the HSE in managing the significant amount of information on treatments for COVID-19. This COVID-19 Evidence Review Group is comprised of evidence synthesis practitioners from across the National Centre for Pharmacoeconomics (NCPE), Medicines Management Programme (MMP) and the National Medicines Information Centre (NMIC). The group respond to queries raised via the Office of the Chief Clinical Officer, National Clinical Programmes and the Department of Health and respond in a timely way with the evidence review supporting the query.
In order to provide timely information to decision makers a rapid evidence review is the chosen methodology.
Rapid Evidence Reviews Completed
ERG RER for Neutralising Monoclonal Antibodies for COVID-19
Clinical evidence for thromboprophylaxis in the management of COVID-19 FINAL Version 4
Antivirals for treatment of COVID-19 A Rapid Evidence Review Version 15
Tocilizumab in the management of COVID-19: A Rapid Evidence Review
Intravenous immunoglobulin for the treatment of COVID-19: A Rapid Evidence Review
Search Strategy for Evidence Reviews in COVID-19
Pharmacological prophylaxis of COVID-19 in healthcare workers or contact cases with COVID-19: A Rapid Evidence Review
Hydroxychloroquine in combination with azithromycin for the treatment of COVID-19: A Rapid Evidence Review
